SUMMARY This study was designed to assess the contribution of thromboxane A 2 to high blood pressure in rats with angiotensin II (Ang ID-salt hypertension. Hypertension was induced in rats drinking 0.15 M NaCl by infusion of Ang II (125 ng/min i.p.) for 12 days. Relative to values hi waterdrinking rats without Ang II infusion, Ang II-salt hypertensive rats exhibited augmentation (p < 0.05) of blood pressure (from 129 ± 3 to 217 ± 12 nun Hg), urinary thromboxane B 2 excretion (from 5.4 ± 0.9 to 25.4 ±2.1 ng/day), and thromboxane B 2 release from renal cortex slices (from 71.3 ± 6.7 to 121.1 ± 14.4 pg/mg) and aortic rings (from 28.8 ± 2.9 to 115.8 ± 12.8 pg/mg). Treatment with an inhibitor of thromboxane A 2 synthetase, UK 38485, had no effect on blood pressure hi normotenslve and Ang II-salt hypertensive rats. Treatment with a thromboxane A 2 receptor blocker, SQ 29548, decreased blood pressure in Ang II-salt hypertensive rats from 191 ± 9 to 152 ± 9 mm Hg after 3 hours, but it had no effect on blood pressure hi normotensive rats. Since SQ 29548 interfered with the pressor effects of the prostaglandin endoperoxide analogue U-46619, prostaglandin F^, and 9a, 11/3-prostaglandln F 2 , we suggest that the SQ 29548-induced blood pressure reduction in Ang II-salt hypertensive rats is the manifestation of blockade of the vascular actions of one or more endogenous prostanoids including thromboxane A 2 and prostaglandin endoperoxides. If so, pressor prostanoids may be contributory factors in the pathogenesis of severe Ang II-salt hypertension hi rats. 6 accompany the development of hypertension in spontaneously hypertensive rats (SHR). The development of hypertension in rats with subtotal renal ablation and in saline-drinking rats infused with angiotensin II (Ang II) also is accompanied by increased TXB 2 urinary excretion.
I
NCREASED urinary thromboxane B 2 (TXBj) excretion 12 and TXB 2 synthesis by platelet 34 and renal structures 3 ' 6 accompany the development of hypertension in spontaneously hypertensive rats (SHR). The development of hypertension in rats with subtotal renal ablation and in saline-drinking rats infused with angiotensin II (Ang II) also is accompanied by increased TXB 2 urinary excretion. 7 ' 8 Since thromboxane A 2 (TXAj), the biologically active precursor of TXB 2 , produces vasoconstriction and platelet aggregation, 9 the possibility arises that TXA 2 contributes to the pathogenesis of hypertension and associated vascular and renal disturbances in SHR and in other models of hypertension featuring augmentation of TXA 2 synthesis.
Participation of TXA 2 in the mechanisms of hypertension also is suggested by reports that treatment with inhibitors of TXA 2 synthetase lowers blood pressure in SHR 1 ' 21011 and in rats with subtotal renal ablation hypertension, 7 in association with improvement of renal hemodynamic and excretory functions and reduction of hypertension-related structural lesions of the renal microvasculature and glomeruli. 2 ' 7 However, in a recent study, blood pressure in SHR was affected by neither a TXA 2 synthesis inhibitor nor a TXA 2 receptor antagonist/ indicating that it is premature to assign to TXA 2 a role in the pathogenesis of hypertension.
In saline-drinking rats, chronic infusion of Ang II causes severe hypertension associated with increased urinary excretion and glomerular synthesis of TXB 2 . 8 The present study was designed to assess the contribution of TXA 2 to high blood pressure in rats with Ang II-salt hypertension. To this end, we investigated the effect of a TXA 2 synthesis inhibitor and of a TXA 2 receptor antagonist on blood pressure in normotensive rats and in rats with Ang II-salt hypertension of 12 days' duration.
Materials and Methods
Studies were conducted on male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN, USA) weighing 200 to 250 g. The animals were housed in individual metabolism cages or in group cages and were kept in a temperature-controlled (24 °Q and humidity-controlled (50%) room that was illuminated between 600 PRESSOR EICOSANOIDS AND HYPERTENSION/Afistry and Nasjletti and 1800; they were fed ad libitum a standard chow (Ralston Purina, St. Louis, MO, USA).
Protocol 1
The purpose of the study using Protocol 1 was to contrast normotensive rats and rats with Ang II-salt hypertension in terms of urinary TXB 2 excretion and rate of TXB 2 production by vascular and renal tissues in vitro.
An Alzet osmotic minipump (Model 2002, Alza, Palo Alto, CA, USA) filled with Ang E ([De^-Ang H, Sigma Chemical, St. Louis, MO, USA) or with vehicle only (0.01 N acetic acid) was placed through a 1-cm midline incision in the abdominal cavity of rats anesthetized with methoxyflurane; the calculated infusion rate of Ang II was 125 ng/min. Animals infused with Ang II drank saline (0.15 M NaCl) throughout the study, whereas animals infused with vehicle drank tap water only. On the 12th day of Ang II or vehicle infusion, a 24-hour urine sample for measurement of TXB 2 was collected into containers kept in dry ice. Once urine sampling was completed, systolic blood pressure was determined by tail sphygmography (Narco Bio-Systems, Houston, TX, USA) after warming the rats at 37°C for 10 minutes. Subsequently, the animals were anesthetized with methoxyflurane, the abdomen and the thorax were exposed through a midline incision, all blood was removed from the animal by exsanguination coupled to transcardiac perfusion with Krebs-Ringer solution, and the thoracic aorta, the superior mesenteric artery, and one kidney were excised for estimation of in vitro TXB 2 release.
The concentration of TXB 2 in urine was measured by radioimmunoassay 12 after prostanoids were purified according to a published method. 13 The urinary excretion of TXB 2 was calculated as the product of a 24-hour urine volume and urinary TXB 2 concentration and was expressed as nanograms per 24 hours. In six normal rats, urinary TXB 2 excretion measured at 4-day intervals over a 20-day period ranged between 4.3 ± 0.6 and 7.5 ± 0.8 ng/day. The rate of TXB 2 release from blood-free vascular and renal tissues in vitro was estimated as described previously for other prostanoids. 13 Briefly, slices of renal cortex and rings of thoracic aorta and superior mesenteric artery were placed in 20-ml flasks containing Krebs-Ringer solution (2.0 ml) and were incubated for 20 minutes at 37 °C in an atmosphere of 95% O 2 , 5% CO 2 with 100 cycle/min agitation; the TXB 2 released into the medium was measured by radioimmunoassay, 12 and the results are expressed as picograms of immunoreactive TXB 2 released during the 20-minute incubation period per milligram dry tissue.
Protocol 2
The purpose of the study using Protocol 2 was to investigate in normotensive and in Ang II-salt hypertensive rats the effect on blood pressure of treatment with UK 38485 ([3-lH-imidazol-lyl-methyl]-2-methyl-lH-indole-1-propanoic acid; Pfizer Pharmaceuticals) to inhibit TXA 2 synthetase 4 or with SQ 29548 Saline-drinking rats infused with Ang II and waterdrinking rats infused with vehicle only were prepared as described in Protocol 1. Eleven days after the onset of Ang II or vehicle infusion, the rats were anesthetized with an i.m. injection of xylazine (13 mg/kg) and ketamine hydrochloride (87 mg/kg) and the left femoral artery and vein were cannulated with polyethylene tubing for blood pressure recording and drug administration, respectively. The indwelling catheters, filled with saline containing heparin (100 IU/ml) and plugged with metal rod pins, were exteriorized at the nape of the neck. One day later, the awake rats were placed in plastic holders and the arterial cannula was connected to a pressure transducer (Model P23ID, Statham, Oxnard, CA, USA) connected to a polygraph (Model 7D, Grass, Quincy, MA, USA).
Normotensive and Ang II-salt hypertensive rats were left undisturbed for 60-90 minutes before being treated with UK 38485 dissolved in 0.1 M NaOH and adjusted to pH 8.5 with 0.1 M HC1, with SQ 29548 dissolved in 0.15 M NaCl containing 15 mM NajCOj, or with the appropriate drug vehicle. UK 38485 treatment was initiated by i. v. injection of a 30 mg/kg bolus followed by i.v. infusion at 15 mg/kg/hr for 3 hours. SQ 29548 treatment was initiated by i.v. injection of a 2 mg/kg bolus followed by i.v. infusion at 2 mg/kg/hr for 3 hours. Three hours after the onset of treatment with UK 38485 or with its vehicle, blood was sampled from the femoral artery cannula of Ang II-salt hypertensive rats and was left to clot in a glass tube at 37 °C for 1 hour; after centrifugation, the serum was frozen until the concentration of TXB 2 was measured by radioimmunoassay in unextracted, appropriately diluted serum samples. Following blood sampling, the rats were anesthetized with methoxyflurane, the abdomen and the thorax were exposed through a midline incision, blood was removed from the animal by exsanguination coupled to transcardiac perfusion with Krebs-Ringer solution, and the thoracic aorta and one kidney were excised for estimation of TXB 2 release from aortic rings and renal cortical slices incubated as described in Protocol 1.
Protocol 3
The purpose of the study using Protocol 3 was to ascertain the effectiveness and specificity of SQ 29548 as a TXA 2 receptor blocker. Normal rats were prepared with indwelling femoral arterial and venous catheters as described in Protocol 2. One day later, the effect on blood pressure of prostanoid and nonprostanoid pressor agents injected as an i.v. bolus was investigated in normotensive rats with and without SQ 29548 pretreatment (2 mg/kg i.v. bolus injection followed by 2 mg/kg/hr i.v. infusion). The pressor agents included in the study were U-46619, 15(S)-hydroxy-lla,9a (epoxy-methano)prosta-5Z-dienoic acid (0.5-5.0 pig; Cayman Chemical, Ann Arbor, MI, USA), a prosta- ; prostaglandin F^ (PGFjJ and 9a,ll/3-prostaglandin F 2 (0.5-5.0 /xg; Biomol Research Laboratories, Philadelphia, PA, USA), norepinephrine bitartrate (5-500 ng; Winthrop-Breon, New York, NY, USA), and Ang H (2.5-250 ng; Sigma).
Statistical Analysis
Results are expressed as the means ± SE. The data were analyzed by Student's t tests (Protocols 1 and 3) or by analyses of variance for repeated measurements (Protocol 2). Probability values (p) less than 0.05 were considered significant). Table 1 , the systolic blood pressure of saline-drinking rats infused with Ang II (125 ng/min i.p.) for 12 days was about 88 mm Hg higher (p<0.01) than the blood pressure of water-drinking animals without Ang n infusion. Relative to values in water-drinking normotensive rats, rats with Ang 13-salt hypertension of 12 days' duration exhibited augmentation (p<0.05) in the urinary excretion of immunoreactive TXB 2 and in the net release of immunoreactive TXB 2 from renal cortex slices and from rings of aorta and superior mesenteric artery during incubation in Krebs-Ringer solution for 20 minutes (see Table 1 ). Figure 1 illustrates the blood pressure of water- Figure 2 illustrates the blood pressure of waterdrinking normotensive rats and of rats with Ang Il-salt hypertension of 12 days' duration before and during the administration of SQ 29548 or vehicle. Mean arterial pressure in awake rats with Ang Il-salt hypertension fell from 191 ± 9 mm Hg before SQ 29548 treatment to 165 ± ll(p<0.01), 149±12(p<0.01),and 152±9 mmHg (p<0.01) after 1, 2, and 3 hours of treatment, respectively. In contrast, treatment with SQ 29548 for 3 hours did not affect the blood pressure of water-drinking normotensive rats. Figure 3 depicts the pressor responses to i.v. bolus injections of prostanoid and nonprostanoid agonists in awake normotensive rats with and without pretreatment with SQ 29548 to block TXA 2 receptors. The prostaglandin endoperoxide analogue U-46619, a known agonist for TXA 2 receptors, caused a doserelated elevation of mean blood pressure; that this effect was greatly reduced in rats receiving SQ 29548 is evidence of the ability of the latter to block vascular TXA 2 receptors in vivo. Treatment with SQ 29548 also attenuated the pressor effect of PGF^ and of 9a, 11/3-prostaglandin F 2 , albeit not as much as it attenuated the pressor effect of U-46619. In contrast, the administration of SQ 29548 did not modify the pressor effect of bolus injections of Ang II and norepinephrine.
Results

As shown in
Discussion
This study demonstrates that saline-drinking rats infused with Ang II exhibit severe hypertension associated with increased urinary TXB 2 excretion and TXB 2 release from aortic rings, mesenteric artery rings, and renal cortex slices. The association of hypertension and increased TXB 2 urinary excretion or production (or both) by renal structures was reported first in SHR 1 '*• '• 6 and subsequently in rats with renal ablation hypertension, 7 Dahl salt-sensitive hypertensive rats, 16 and two-kidney, one clip hypertensive rats." Rats with severe hypertension and vascular disease may feature infiltration of the arterial vascular wall by bloodformed elements that are capable of synthesizing TXA 2 . Hence, augmentation of vascular and renal TXB 2 production by vascular and renal cortical tissues in Ang II-salt hypertensive rats may be a secondary event reflecting vascular injury. Inhibitors of TXA 2 synthetase have been reported to reduce arterial blood pressure both in the developmental and the established phases of hypertension in SHR 12 -10 ' " and to interfere with the development of renal ablation hypertension. 7 In the present study, treatment with the TXA 2 synthetase inhibitor UK 38485 greatly reduced the serum TXB 2 concentration and the release of TXB 2 from aortic rings and renal cortical slices, but it did not reduce the arterial blood pressure in rats with Ang II-salt hypertension of 12 days' duration. Yet, based on these findings, one cannot exclude a role for TXA 2 as a contributory factor to Ang II-salt hypertension, as the functional consequence of a reduction in TXA2 due to inhibition of TXA2 synthetase may be obscured by the functional consequence of increased levels of prostaglandin en-762 doperoxide, the precursor of TXA 2 , which is known to cause contraction of vascular smooth muscle and platelet aggregation 9 by interacting with the TXA 2 receptor. Furthermore, UK 38485 treatment did not completely inhibit tissue TXA 2 synthesis.
In contrast to the lack of effect of the TXA 2 synthetase inhibitor UK 38485 on blood pressure, our present study demonstrates that the administration of SQ 29548 causes blood pressure to fall in rats with Ang n-salt hypertension of 12 days' duration. That the blood pressure of normotensive rats was not reduced by treatment with SQ 29548 suggests selectivity in the blood pressure-lowering effect of the drug in Ang IIsalt hypertensive rats. Such a selectivity would be expected if the hypotensive effect of SQ 29548 is the manifestation of interference with a mechanism contributing to set the level of arterial blood pressure in Ang n-salt hypertensive rats but not in normotensive rats.
SQ 29548 is known to block the response of platelets and vascular smooth muscle to TXA 2 and TXA 2 -mimetic agents by preventing the agonist-TXA 2 receptor interaction.
14 ' " Confirming that SQ 29548 blocks TXA 2 receptors in vivo, we found that the pressor effect of U-46619, a stable analogue of prostaglandin H 2 that interacts with the TXA 2 receptor, 1415 was greatly reduced in SQ 29548-treated animals. We also found that SQ 29548 reduced the pressor effect of PGF^ and of 9a, 11/3-prostaglandin F 2 , a metabolite of prostaglandin D 2 . Inasmuch as SQ 29548 pretreatment did not affect the pressor response to bolus injections of Ang II or norepinephrine, it may be concluded that the agent interferes only with prostanoid-induced pressor responses.
Based on the preceding discussion, the blood pressure-lowering effect of SQ 29548 in Ang II-salt hypertensive rats may be the expression of blockade of the vascular actions of one or more endogenous pressor prostanoids, including TXA 2 and prostaglandin endoperoxides. If so, pressor prostanoids may be contributory elements in the pathogenesis of severe Ang II-salt hypertension in rats.
In summary, urinary TXB 2 excretion and the release of TXB 2 from vascular and renal cortical tissues in vitro are increased in rats with severe Ang II-salt hypertension of 12 days' duration. Treatment with an inhibitor of TXA 2 synthetase, UK 38485, did not change the blood pressure of normotensive or of Ang II-salt hypertensive rats. Treatment with a TXA 2 receptor blocker, SQ 29548, lowered blood pressure in Ang II-salt hypertensive but not in normotensive rats. Since SQ 29548 interfered with the rise in blood pressure elicited by a prostaglandin endoperoxide analogue, PGF^, and 9a, 11/3-prostaglandin F 2 , we suggest that the SQ 29548-induced blood pressure reduction in Ang II-salt hypertensive rats is the result of blockade of the vascular actions of one or more endogenous pressor prostanoids including TXA 2 and prostaglandin endoperoxides.
